Portal vein thrombosis and renal dysfunction: a national comparative study of liver transplant recipients for NAFLD versus alcoholic cirrhosis.
alcoholic liver disease
interaction
liver transplantation
nonalcoholic fatty liver disease
nonalcoholic steatohepatitis
overall survival
perioperative mortality
portal vein thrombosis
renal dysfunction
Journal
Transplant international : official journal of the European Society for Organ Transplantation
ISSN: 1432-2277
Titre abrégé: Transpl Int
Pays: Switzerland
ID NLM: 8908516
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
revised:
08
03
2021
received:
22
01
2021
accepted:
19
03
2021
pubmed:
30
3
2021
medline:
3
7
2021
entrez:
29
3
2021
Statut:
ppublish
Résumé
The prevalence of portal vein thrombosis (PVT), renal dysfunction (RD), and simultaneous PVT/RD in liver transplantation (LT) is poorly understood. We analyzed the prevalence of PVT, RD, simultaneous PVT/RD, and the outcomes of adult recipients of LT for nonalcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD) between 2006 and 2016 in the United States. We found that the prevalence of PVT (7.2% → 11.3%), RD (33.8% → 39.2%), and simultaneous PVT/RD (2.4% → 4.5%) has increased significantly over the study period (all P-values <0.05). NAFLD patients had a higher proportion of PVT (14.8% vs. 9.2%), RD (45.0% vs. 42.1%), and simultaneous PVT/RD (6.5% vs. 3.9%; all P-values <0.05). 90-day mortality was 3.8%, 6.3%, 6.8%, and 9.8% for PVT(-)/RD(-), PVT(-)/RD(+), PVT(+)/RD(-), and PVT(+)/RD(+) recipients, respectively (P < 0.01). 5-year survival was 82.1%, 75.5%, 74.8%, and 71.1% for PVT(-)/RD(-), PVT(-)/RD(+), PVT(+)/RD(-), and PVT(+)/RD(+) recipients, respectively (P < 0.05). In conclusion, the prevalence of PVT, RD, and simultaneous PVT/RD has increased among LT recipients, especially for those with NAFLD. The short- and long-term outcomes of recipients with PVT, RD, and simultaneous PVT/RD were inferior to patients without those risk factors irrespective of their indication for LT. No differences in patient outcomes were found between ALD and NAFLD recipients after stratification by risk factors.
Identifiants
pubmed: 33780554
doi: 10.1111/tri.13873
pmc: PMC8360094
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1105-1122Subventions
Organisme : none
ID : na
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 The Authors. Transplant International published by John Wiley & Sons Ltd on behalf of Steunstichting ESOT.
Références
Hepatology. 2008 Dec;48(6):2064-77
pubmed: 19003880
Hepatology. 2001 Feb;33(2):464-70
pubmed: 11172350
Epidemiology. 2007 Nov;18(6):805-35
pubmed: 18049195
Liver Transpl. 2012 May;18(5):549-57
pubmed: 22238251
J Hepatol. 2019 Aug;71(2):313-322
pubmed: 31071367
Exp Clin Transplant. 2014 Jun;12(3):238-40
pubmed: 24907725
HPB (Oxford). 2007;9(5):352-6
pubmed: 18345318
Gut. 2011 May;60(5):702-9
pubmed: 21325171
Am J Gastroenterol. 2018 Nov;113(11):1649-1659
pubmed: 29880964
United European Gastroenterol J. 2018 Feb;6(1):104-111
pubmed: 29435320
World J Gastroenterol. 2014 Nov 14;20(42):15499-517
pubmed: 25400435
Am J Transplant. 2009 Apr;9(4):782-93
pubmed: 19344467
Bull Soc Int Chir. 1967 Sep;26(5):474-88
pubmed: 4913602
Liver Transpl. 2019 Jan;25(1):68-78
pubmed: 30091296
World J Gastroenterol. 2012 Sep 28;18(36):5014-20
pubmed: 23049208
Curr Opin Pulm Med. 2009 Sep;15(5):408-12
pubmed: 19561505
Hepatology. 1996 Jan;23(1):164-76
pubmed: 8550036
Liver Int. 2015 Dec;35(12):2575-83
pubmed: 25977117
Ter Arkh. 2019 Mar 18;91(2):73-81
pubmed: 31094175
Nat Rev Dis Primers. 2018 Sep 13;4(1):23
pubmed: 30213943
World Health Organ Tech Rep Ser. 1995;854:1-452
pubmed: 8594834
PLoS Med. 2015 Oct 06;12(10):e1001885
pubmed: 26440803
World J Hepatol. 2015 Sep 28;7(21):2336-43
pubmed: 26413223
Eur J Gastroenterol Hepatol. 2019 May;31(5):618-625
pubmed: 30920976
J Gastroenterol Hepatol. 2019 Jun;34(6):1088-1092
pubmed: 30307066
Transplant Direct. 2019 Feb 20;5(3):e427
pubmed: 30882032
Transplantation. 2000 May 15;69(9):1873-81
pubmed: 10830225
HPB (Oxford). 2012 Sep;14(9):625-34
pubmed: 22882200
Am J Transplant. 2018 Jan;18 Suppl 1:172-253
pubmed: 29292603
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):188-195
pubmed: 27913479
Liver Transpl. 2017 Oct;23(S1):S59-S63
pubmed: 28834305
Ann Intern Med. 2013 Dec 17;159(12):835-47
pubmed: 24145991
World J Gastroenterol. 2013 Mar 21;19(11):1707-17
pubmed: 23555159
Hepatology. 2000 Apr;31(4):864-71
pubmed: 10733541
Transpl Int. 2018 Dec;31(12):1318-1329
pubmed: 30230053
Liver Int. 2017 Feb;37(2):290-298
pubmed: 27258535
J Hepatol. 2019 Nov;71(5):1038-1050
pubmed: 31442476
Am J Gastroenterol. 2017 Apr;112(4):581-587
pubmed: 28195177
Aliment Pharmacol Ther. 2017 Nov;46(9):825-835
pubmed: 29023881
Liver Transpl. 2001 Feb;7(2):125-31
pubmed: 11172396
N Engl J Med. 2011 Jul 14;365(2):147-56
pubmed: 21751907
Clin Liver Dis. 2009 Feb;13(1):109-116
pubmed: 19150315
Exp Clin Transplant. 2016 Feb;14(1):79-85
pubmed: 26581602
Clin Gastroenterol Hepatol. 2015 Mar;13(3):585-93
pubmed: 25459555
Clin Kidney J. 2014 Oct;7(5):442-9
pubmed: 25878775
Gut. 2007 Sep;56(9):1310-8
pubmed: 17389705
Liver Transpl. 2010 Aug;16(8):999-1005
pubmed: 20677291
Kidney Int. 2005 Jul;68(1):362-70
pubmed: 15954928
PLoS Med. 2014 Jul 22;11(7):e1001680
pubmed: 25050550
Metabolism. 2018 Feb;79:64-76
pubmed: 29137912
Gastroenterology. 2017 Apr;152(5):1090-1099.e1
pubmed: 28088461
Gastroenterol Rep (Oxf). 2017 May;5(2):127-137
pubmed: 28533910
Clin Transplant. 2014 Jun;28(6):713-21
pubmed: 24654688
Clin Gastroenterol Hepatol. 2014 Mar;12(3):394-402.e1
pubmed: 24076414
Clin Transl Gastroenterol. 2018 Mar 6;9(3):140
pubmed: 29511162
Crit Care Clin. 2015 Oct;31(4):737-50
pubmed: 26410141
Gut. 2011 Sep;60(9):1254-9
pubmed: 21504996